[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Center for Health Sciences, Serbia\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":117},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,46,70,94],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":4},"100624470","microbiome-targeted-enhancement-of-neurocognition-with-probiotics-riboflavin-combination-100624470",false,"NCT07410052","Microbiome-Targeted Enhancement of Neurocognition With Probiotics-Riboflavin Combination","Microbiome-Targeted Enhancement of Neurocognition With Probiotics-Riboflavin Combination (MENTOR)","MENTOR","Inclusion Criteria:\n\n* Age \\> 65 years\n* MoCA scores 18-25 points\n* BMI of 20.0 - 29.9 kg\u002Fm2 at screening\n* Stable body weight (≤ 5% change) over the past 3-months\n* Willing to avoid consuming gut microbiome-modulating dietary supplements within 4 weeks prior to the baseline visit\n* Subjects will abstain from vitamin B2-rich food intake as per pre-defined list\n* Maintain current level of physical activity\n* Be willing and able to comply with trial protocol\n\nExclusion Criteria:\n\n* Severe chronic disease and acute injuries\n* History of dietary supplement use four weeks before enrolment\n* Organic gastrointestinal (GI) disorders\n* Bowel surgery or short bowel syndrome\n* Gut-altering medications two months before enrolment\n* Is currently using systemic steroids, proton pump inhibitors, H2 blocker, antacid\n* History of drug and\u002For alcohol abuse at the time of enrolment\n* Smoker or vaper\n* Has made any major dietary changes in the past 3 months prior to baseline\n* Has a currently active eating disorder\n* Has food allergies or other issues with foods",true,"ALL","65 Years",{"count":21,"type":22},28,"ESTIMATED","INTERVENTIONAL",[25],"NA","This randomized, double-blind, placebo-controlled trial will evaluate whether 12 weeks of supplementation with the probiotic Lactobacillus rhamnosus GG combined with colon-delivered riboflavin will improve cognitive performance and brain physiology in older adults with memory complaints. The study will assess changes in cognitive outcomes together with neurophysiological markers to explore potential gut-brain axis mechanisms. Through its rigorous design, the trial will aim to determine whether targeted modulation of the intestinal environment can support brain function and cognitive health in aging.",[28],"Cognitive Deficits, Mild",[30,31,32,33],"Bioenergetics","Sleep quality","Cognition","Oxygenation","NOT_YET_RECRUITING","2026-02-07",{"date":37,"type":38},"2026-02-13","ACTUAL",{"date":40,"type":22},"2026-04-15",{"date":42,"type":22},"2027-08-15",{"name":44,"class":45},"Center for Health Sciences, Serbia","OTHER",{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":17,"sex":18,"minAge":54,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":23,"phases":57,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":64,"startDateStruct":65,"completionDateStruct":66,"leadSponsor":68,"locationsCount":69},"100624471","supersaturated-hydrogen-rich-water-for-outpatients-with-persistent-excess-weight-100624471","NCT07410065","Supersaturated Hydrogen-Rich Water for Outpatients With Persistent Excess Weight","Supersaturated Hydrogen-Rich Water for Outpatients With Persistent Excess Weight (HOPE)","HOPE","Inclusion Criteria:\n\n* Age \\> 18 years\n* Body mass index \\> 25.0 kg\u002Fm2 (persisted for at least six months before screening)\n* Stable on their therapy (if any) for ≥ 3 months\n* Free of acute disorders and severe chronic diseases\n* Informed consent signed\n* Normal fasting breath hydrogen levels \\\u003C 15 ppm\n\nExclusion Criteria:\n\n* History of dietary supplement use 4 weeks before the study commences\n* Abnormal values for lab clinical chemistry not related with stiyd outcomes (\\> 2 SD)\n* No consent to randomization\n* Unwillingness to return for follow-up analysis\n* Participation in other clinical trials\n* Participants starting or changing major treatments during the study period","18 Years",{"count":56,"type":22},120,[25],"The Supersaturated Hydrogen-Rich Water for Outpatients with Persistent Excess Weight (HOPE) study is a Phase III, multicenter, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of daily consumption of supersaturated hydrogen-rich water in adults with persistent excess body weight. The trial investigates whether sustained exposure to molecular hydrogen can favorably influence body composition and key metabolic outcomes compared with a placebo water lacking dissolved hydrogen. By enrolling outpatients across multiple centers and applying rigorous blinding and randomization procedures, HOPE aims to generate high-quality clinical evidence on the potential role of hydrogen-rich water as a non-pharmacological, adjunctive strategy for weight management and metabolic health.",[60],"Overweight",[62,63],"Metabolism","Hydrogen",{"date":37,"type":38},{"date":40,"type":22},{"date":67,"type":22},"2027-02-15",{"name":44,"class":45},1,{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":17,"sex":18,"minAge":78,"maxAge":4,"enrollmentInfo":79,"targetDuration":4,"studyType":23,"phases":81,"briefSummary":82,"conditions":83,"keywords":4,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":69},"100614871","creatine-hcl-supplementation-in-sarcopenia-a-randomized-controlled-study-100614871","NCT07285226","Creatine HCl Supplementation in Sarcopenia: A Randomized Controlled Study","Impact of 12-Week Creatine HCl Supplementation on Body Composition, Functional Muscle and Brain Performance, Blood Biomarkers, and Tissue Creatine Levels in Older Adults With Sarcopenia","SARCOPA","Inclusion Criteria:\n\n* Age \\> 60 years\n* Low muscle strength by handgrip (SDOC criteria for sarcopenia): \\\u003C 35.5 kg in men and \\\u003C 20 kg in women\n* Sign free and informed consent\n* Demonstrate interest, conditions and availability to participate\n\nExclusion Criteria:\n\n* Patients undergoing interventional treatment for sarcopenia\n* Physical amputation\n* Cognitive impairment (MSSE \\\u003C 25)\n* Unwillingness to return for follow-up analysis\n* Participation in other clinical trials","60 Years",{"count":80,"type":22},30,[25],"The CONCRET-SARCOPA trial is a 12-week, double-blind, randomized controlled study designed to evaluate the efficacy of creatine HCl supplementation in older adults with sarcopenia. The trial investigates whether daily creatine HCl improves body composition, enhances functional muscle and cognitive performance, and favorably alters key blood biomarkers associated with muscle health and metabolic status. Additionally, the study assesses changes in tissue creatine levels using non-invasive and biochemical methods to clarify mechanistic responses to supplementation. Findings from this trial will provide critical evidence on the therapeutic potential of creatine HCl as a targeted nutritional strategy for managing sarcopenia in the geriatric population.",[84],"Sarcopenia","RECRUITING","2025-12-27",{"date":88,"type":38},"2026-01-02",{"date":90,"type":38},"2025-12-01",{"date":92,"type":22},"2026-09-15",{"name":44,"class":45},{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":100,"eligibilityCriteria":101,"healthyVolunteers":17,"sex":18,"minAge":54,"maxAge":102,"enrollmentInfo":103,"targetDuration":4,"studyType":23,"phases":105,"briefSummary":106,"conditions":107,"keywords":4,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":69},"100617377","effects-of-different-vitamin-d3-formulations-in-vitamin-d-deficient-adults-100617377","NCT07317830","Effects of Different Vitamin D3 Formulations in Vitamin D-Deficient Adults","The Effects of Eight Weeks of Supplementation With Two Vitamin D₃ Formulations in Adults With Subclinical and Clinical Vitamin D Deficiency: A Randomized Controlled Superiority Pilot Trial","AMORPH-D","Inclusion Criteria:\n\n* Adults aged 18 years and over\n* Serum 25(OH)D \\\u003C 75 nmol\u002FL\n* BMI 18.5 - 29.9 kg\u002Fm2\n* Free of clinically significant acute disorders and severe chronic diseases\n* No planned travel to high-UV destinations or tanning bed use during the trial\n* Willing to avoid non-study vitamin D supplements\n* Able to give written informed consent and comply with study visits\n* Submitted informed consent\n\nExclusion Criteria:\n\n* Pregnancy of breast feeding\n* Underweight or obesity\n* History of any dietary supplement use within 8 weeks before screening\n* Medications that materially alter vitamin D metabolism or calcium balance\n* Subjects with a history of medicine or alcohol abuse\n* Abnormal values for lab clinical chemistry (\\> 2 SD)\n* Unwillingness to return for follow-up analysis\n* Participation in other clinical trials within 60 days prior to screening","80 Years",{"count":104,"type":22},20,[25],"This randomized controlled superiority pilot trial will evaluate the efficacy of two vitamin D3 formulations administered over eight weeks in adults with subclinical or clinical vitamin D deficiency. The study will compare changes in serum 25-hydroxyvitamin D concentrations between formulations, as well as the proportion of participants who will achieve vitamin D sufficiency. Both formulations are expected to improve vitamin D status, with the hypothesis that one formulation will demonstrate superior bioavailability, resulting in greater and faster increases in circulating 25-hydroxyvitamin D. The findings will provide preliminary evidence to inform formulation selection and dosing strategies for correcting vitamin D deficiency and will support the design of larger, confirmatory trials.",[108],"Vitamin D Deficiency","2025-12-24",{"date":111,"type":38},"2026-01-05",{"date":113,"type":22},"2025-12-15",{"date":115,"type":22},"2026-06-15",{"name":44,"class":45},""]